Abstract
Colchicine is a tricyclic alkaloid extracted from the herbaceous plant Colchicum autumnale. Known since antiquity for its therapeutic efficacy in the treatment of gout, colchicine was reintroduced in 19th century pharmacopeia, thanks to the work of the French chemists and pharmacists Pierre-Joseph Pelletier (1788-1842) and Joseph Bienaimé Caventou (1795-1877) who in 1819, isolated a peculiar substance in the roots of Colchicum autumnale. In 1833, the substance was further analyzed by the German pharmacist and chemist Philipp Lorenz Geiger (1785-1836), who coined the name colchicine. In 1884, the French pharmacist Alfred Houde (1854-1919) produced for the first time pure crystallized colchicine in granules of 1milligram which is still sold under this trade name in several countries. In the last two centuries, colchicine's indications were furthermore expanded. From anti-gout drug during antiquity and a diuretic in 19th century, colchicine is currently administered in several affections such as Adamantiades-Behcet's disease, familial Mediterranean fever, pericarditis and atrial fibrillation.
Keywords: Colchicum, pierre-joseph pelletier, joseph bienaimé caventou, history of pharmacology, gout, atrial fibrillation.
Current Pharmaceutical Design
Title:Isolating Colchicine in 19th Century: An Old Drug Revisited
Volume: 24 Issue: 6
Author(s): Marianna Karamanou*, Gregory Tsoucalas, Konstantinos Pantos and George Androutsos
Affiliation:
- University Institute of History of Medicine and Public Health, Lausanne,Switzerland
Keywords: Colchicum, pierre-joseph pelletier, joseph bienaimé caventou, history of pharmacology, gout, atrial fibrillation.
Abstract: Colchicine is a tricyclic alkaloid extracted from the herbaceous plant Colchicum autumnale. Known since antiquity for its therapeutic efficacy in the treatment of gout, colchicine was reintroduced in 19th century pharmacopeia, thanks to the work of the French chemists and pharmacists Pierre-Joseph Pelletier (1788-1842) and Joseph Bienaimé Caventou (1795-1877) who in 1819, isolated a peculiar substance in the roots of Colchicum autumnale. In 1833, the substance was further analyzed by the German pharmacist and chemist Philipp Lorenz Geiger (1785-1836), who coined the name colchicine. In 1884, the French pharmacist Alfred Houde (1854-1919) produced for the first time pure crystallized colchicine in granules of 1milligram which is still sold under this trade name in several countries. In the last two centuries, colchicine's indications were furthermore expanded. From anti-gout drug during antiquity and a diuretic in 19th century, colchicine is currently administered in several affections such as Adamantiades-Behcet's disease, familial Mediterranean fever, pericarditis and atrial fibrillation.
Export Options
About this article
Cite this article as:
Karamanou Marianna*, Tsoucalas Gregory, Pantos Konstantinos and Androutsos George, Isolating Colchicine in 19th Century: An Old Drug Revisited, Current Pharmaceutical Design 2018; 24 (6) . https://dx.doi.org/10.2174/1381612824666180115105850
DOI https://dx.doi.org/10.2174/1381612824666180115105850 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design Novel Therapies in OA
Current Drug Targets Systemic Fungal Infections Caused by Candida Species: Epidemiology, Infection Process and Virulence Attributes
Current Drug Targets Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Tuberculous Pericarditis
Current Cardiology Reviews An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Motility Disorders, Functional Gastrointestinal Disorders, Inflammatory Bowel Disease and Cardiac Rhythm Disturbances - Is there a Link? Review of Literature
Current Drug Targets Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases
Current Molecular Pharmacology The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Mixed Connective Tissue Disease, a Roundabout to Rheumatic Diseases?
Current Rheumatology Reviews Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology